Amina Ahmed, MD
Gynecologic Oncology · Chicago, ILNPI 1154372068
Payments from drug & device makers
Across 786 payments — averaging $1398.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$395K
- GSK$376K
- Tesaro, Inc.$133K
- AbbVie$99K
- Merck$57K
- AstraZeneca$25K
- plus $14K from 9 others
What the payments were for
- Consulting fees$115,22410%
- Speaking & faculty fees$850,47477%
- Travel & lodging$116,62111%
- Food & beverage$16,6852%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 270 | $394,698 |
| GSK | 218 | $376,436 |
| Tesaro, Inc. | 141 | $132,723 |
| AbbVie | 51 | $98,627 |
| Merck | 59 | $57,471 |
| AstraZeneca | 18 | $24,970 |
| Immunogen, Inc. | 9 | $12,001 |
| Intuitive Surgical | 8 | $1,571 |
| Novartis | 1 | $183 |
| Siemens Medical Solutions USA, Inc. | 1 | $132 |
| Boehringer Ingelheim | 4 | $93 |
| Mindray DS USA, Inc. | 3 | $72 |
| Tempus AI, Inc | 1 | $71 |
| Genentech USA, Inc. | 1 | $14 |
| Avion Pharmaceuticals | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LENVIMA$392,766
- ZEJULA$318,219
- JEMPERLI$171,352
- Elahere$106,343
- KEYTRUDA$51,548
- LYNPARZA$24,441
- Da Vinci Surgical System$1,495
- Fabhalta$183
- ACUSON SC2000 Diagnostic Ultrasound System$132
How this compares
$1,099,075 in reported general payments places this provider in the 95th percentile of 64 gynecologic oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Letrozole | 26 | $464 |
| Nystatin | 13 | $181 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $101 |
| Ibuprofen | 16 | $40 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Chicago
- John MoroneyChicago$3.3M
- Dario RoqueChicago$1.2M
- Emma BarberChicago$897K
- Julian SchinkChicago$388K
- Jenna MarcusChicago$381K
- Summer DewdneyChicago$241K
- Emily HinchcliffChicago$142K
- Shannon MaclaughlanChicago$121K
- Kathryn MillsChicago$32K
- Wilberto Nieves-NeiraChicago$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.